EAM
PTCT icon

Eagle Asset Management’s PTC Therapeutics PTCT Stock Holding History

Eagle Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-433,834
Closed -$21.3M – 613
2021
Q1 		$21.3M Buy
433,834
+59,959
+16% +$3.56M 0.09% 233
2020
Q4 		$25.2M Sell
373,875
-70,903
-16% -$4.18M 0.14% 203
2020
Q3 		$21M Buy
444,778
+10,843
+2% +$534K 0.11% 208
2020
Q2 		$22M Buy
433,935
+233,212
+116% +$11.5M 0.12% 204
2020
Q1 		$8.95M Buy
200,723
+113,712
+131% +$5.73M 0.06% 282
2019
Q4 		$4.18M Buy
+87,011
New +$3.7M 0.02% 434

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Eagle Asset Management's PTCT Position: Q2 2021 in Review

Eagle Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 433,834 shares — an estimated $21.3M sold.

Eagle Asset Management first reported a position in PTCT in Q4 2019 and held it in 6 quarters. The position peaked at $25.2M in Q4 2020. 182 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

  • Eagle Asset Management reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Eagle Asset Management sold 433,834 PTC Therapeutics shares in Q2 2021, an estimated $21.3M.
  • Eagle Asset Management first reported a position in PTC Therapeutics in Q4 2019 and held it in 6 quarters.
  • Eagle Asset Management's PTC Therapeutics position peaked at $25.2M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Eagle Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.